14,521 Shares in Immunome, Inc. (NASDAQ:IMNM) Purchased by Kennedy Capital Management LLC

Kennedy Capital Management LLC purchased a new stake in Immunome, Inc. (NASDAQ:IMNM) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 14,521 shares of the company’s stock, valued at approximately $154,000.

A number of other large investors have also recently modified their holdings of IMNM. Geode Capital Management LLC raised its stake in Immunome by 13.6% in the third quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company’s stock valued at $17,657,000 after purchasing an additional 144,557 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Immunome by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 457,252 shares of the company’s stock valued at $4,856,000 after buying an additional 14,775 shares in the last quarter. Magnus Financial Group LLC lifted its holdings in shares of Immunome by 107.8% during the 4th quarter. Magnus Financial Group LLC now owns 53,536 shares of the company’s stock worth $569,000 after acquiring an additional 27,777 shares during the last quarter. Barclays PLC grew its position in Immunome by 125.9% in the third quarter. Barclays PLC now owns 105,886 shares of the company’s stock worth $1,547,000 after acquiring an additional 59,016 shares in the last quarter. Finally, Wellington Management Group LLP increased its stake in Immunome by 137.1% in the third quarter. Wellington Management Group LLP now owns 140,690 shares of the company’s stock valued at $2,057,000 after acquiring an additional 81,354 shares during the last quarter. Institutional investors own 44.58% of the company’s stock.

Analyst Ratings Changes

IMNM has been the subject of several research analyst reports. Stephens reaffirmed an “overweight” rating and set a $30.00 price target on shares of Immunome in a research note on Thursday, March 20th. Wedbush reaffirmed an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research note on Thursday, March 20th. Guggenheim decreased their price target on shares of Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a research note on Thursday, March 20th. Lake Street Capital started coverage on shares of Immunome in a report on Wednesday, April 2nd. They set a “buy” rating and a $23.00 target price on the stock. Finally, Lifesci Capital began coverage on shares of Immunome in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 price target for the company. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $25.14.

Insider Buying and Selling at Immunome

In other news, CTO Philip Tsai acquired 12,300 shares of the business’s stock in a transaction on Monday, March 24th. The shares were acquired at an average cost of $8.42 per share, with a total value of $103,566.00. Following the transaction, the chief technology officer now owns 33,300 shares in the company, valued at $280,386. The trade was a 58.57 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Clay B. Siegall bought 150,000 shares of Immunome stock in a transaction on Friday, January 31st. The shares were purchased at an average price of $7.75 per share, for a total transaction of $1,162,500.00. Following the acquisition, the chief executive officer now directly owns 669,636 shares in the company, valued at approximately $5,189,679. This trade represents a 28.87 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 306,400 shares of company stock valued at $2,322,995. 8.60% of the stock is currently owned by company insiders.

Immunome Trading Up 0.7 %

Immunome stock opened at $7.40 on Wednesday. Immunome, Inc. has a 1-year low of $5.15 and a 1-year high of $19.07. The firm has a market cap of $643.44 million, a P/E ratio of -0.91 and a beta of 2.05. The firm has a 50-day moving average of $8.38 and a 200-day moving average of $10.50.

Immunome (NASDAQ:IMNM) last posted its earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.16). Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. The business had revenue of $2.74 million for the quarter, compared to analysts’ expectations of $3.07 million. Research analysts forecast that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.